Evidence map›Paper›PMID 35456625›Full record

ReviewPharmaceutics2022

Mesenchymal Stem/Stromal Cells in Organ Transplantation.

Dayanand Deo, Misty Marchioni, Prakash Rao

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Simultaneous Co-transplantation for Highly Efficient Cell Therapy.Current stem cell research & therapy · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. De novo SIX2 activation in human kidneys treated with neonatal kidney stem/progenitor cells.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Dayanand DeoPersonalized Transplant Medicine Institute, 691 Central Avenue, New Providence, NJ 07974, USA.ORCID 0000-0001-7212-2646
Misty MarchioniPersonalized Transplant Medicine Institute, 691 Central Avenue, New Providence, NJ 07974, USA.
Prakash RaoPersonalized Transplant Medicine Institute, 691 Central Avenue, New Providence, NJ 07974, USA.
Providence College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organ transplantation is essential and crucial for saving and enhancing the lives of individuals suffering from end-stage organ failure. Major challenges in the medical field include the shortage of organ donors, high rates of organ rejection, and long wait times. To address the current limitations and shortcomings, cellular therapy approaches have been developed using mesenchymal stem/stromal cells (MSC). MSC have been isolated from various sources, have the ability to differentiate to important cell lineages, have anti-inflammatory and immunomodulatory properties, allow immunosuppressive drug minimization, and induce immune tolerance towards the transplanted organ. Additionally, rapid advances in the fields of tissue engineering and regenerative medicine have emerged that focus on either generating new organs and organ sources or maximizing the availability of existing organs. This review gives an overview of the various properties of MSC that have enabled its use as a cellular therapy for organ preservation and transplant. We also highlight emerging fields of tissue engineering and regenerative medicine along with their multiple sub-disciplines, underlining recent advances, widespread clinical applications, and potential impact on the future of tissue and organ transplantation.

Indexed as

3D bioprintingdecellularizationimmunomodulationmesenchymal stem/stromal cellsorganoidsparacrine effectsregenerative medicinetissue engineeringtransplantationtransplant tolerance

Identifiers

PMID35456625
PMCPMC9029865
OpenAlexW4224312109

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.